Organoids Market (2033): Intestinal Organoids, Biomedical Research & Drug Discovery Growth in United States Expansion

The Global Organoids Market reached US$ 1.91 Billion in 2025 and is expected to reach US$ 6.41 Billion in 2033, growing at a CAGR of 16.5% during the forecast period (2026-2033). Growth is driven by the rising prevalence of chronic diseases, increasing demand for human-relevant disease models, adoption of personalized medicine, and advancements in stem cell and 3D cell culture technologies.

Download your exclusive sample report today (corporate email gets priority access):
https://www.datamintelligence.com/download-sample/organoids-market?sindhuri

Organoid technologies are increasingly used in drug discovery, biomedical research, cancer research, personalized medicine, regenerative medicine, infectious disease research, and biobanking. Advances in 3D cell culture, automated platforms, organoid biobanking, organ-on-chip technologies, AI-assisted analysis, and high-throughput screening are further improving scalability and research accuracy.

North America dominates the market due to strong biotechnology investments, advanced research infrastructure, pharmaceutical R&D, and government funding. Europe is supported by growing precision medicine and biomedical research initiatives, while Asia-Pacific is expected to witness rapid growth due to expanding biopharmaceutical capabilities, improving research infrastructure, government support, and increasing investments in countries such as China, Japan, India, and Australia.

Organoids Market: Competitive Intelligence
Thermo Fisher Scientific Inc., Merck KGaA, QIAGEN N.V., Meridian Bioscience Inc., New England Biolabs, Mirus Bio LLC, ACROBiosystems, Danaher Corporation, ATCC, and AxoSim are key players in the global Organoids Market. These companies offer organoid culture media, reagents, 3D cell culture technologies, research tools, and related solutions.

Competition is driven by culture reproducibility, scalability, standardization, automation, high-throughput capabilities, and application-specific solutions. Leading companies are focusing on improving organoid workflows, expanding biobanking capabilities, integrating AI and automation, and strengthening collaborations with pharmaceutical, biotechnology, and academic research organizations.

Get Customization in the report as per your requirements:
https://www.datamintelligence.com/customize/organoids-market?sindhuri

Recent Key Developments - United States & North America
✅ August 2026: Molecular Devices and HeartBeat.bio announced the upcoming availability of the 3D ReadyTM Cardioid Supplement Kit, combining cardiac organoid biology with automated workflows to improve the reproducibility and scalability of human cardiac models for drug discovery, toxicity testing, and safety assessment.

✅ July 2026: PBS Biotech joined Organoid COMMONS, supporting efforts to establish scalable biomanufacturing standards and frameworks for transitioning organoid technologies from early-stage research toward commercial applications and reducing reliance on animal models.

✅ June 2026: Researchers at UCLA Health developed an AI-enabled platform integrating 3D bioprinting, advanced imaging, and artificial intelligence to continuously track drug responses across patient-derived tumor organoids, strengthening applications in precision oncology and personalized treatment selection.

Recent Key Developments - Japan & Asia-Pacific
✅ August 2026: Research published in Nature demonstrated that human brain organoids could be maintained for more than five years, allowing them to develop molecular and cellular characteristics associated with later stages of human brain development and creating new opportunities for neuroscience and disease research.

✅ June 2026: Alps Group launched a patient-derived organoid (PDO) program in Malaysia through a research collaboration focused on personalized cancer treatment and preclinical drug screening, supporting the expansion of organoid-based precision oncology in Southeast Asia.

✅ 2026: Increasing research activity across Asia-Pacific is strengthening the use of organoids for personalized medicine, disease modeling, and translational research, with advances increasingly focused on improving model complexity, scalability, and clinical applicability.

Recent Key Developments - Product & Technology Innovation
✅ August 2026 - Long-Lived Brain Organoids: Researchers achieved a major longevity milestone by maintaining human brain organoids in culture for more than five years, enabling extended investigation of brain maturation and age-related neurological processes.

✅ July 2026 - Tumor Organoid Platforms: Weill Cornell researchers developed a library of 220 patient-derived tumor organoids, advancing the use of tumor models for preclinical testing, treatment evaluation, and precision oncology.

✅ June-August 2026 - AI, Automation & Scalable Organoids: Integration of organoids with AI-driven imaging, automation, bioprinting, and high-throughput workflows is accelerating drug discovery and improving the reproducibility and scalability of human-relevant disease models.

M&A / Strategic Activity
Recent strategic acquisitions, partnerships, and ecosystem developments shaping the Organoids Market:

Merck KGaA / MilliporeSigma - Acquisition of HUB Organoids
Merck KGaA's Life Science business completed the acquisition of HUB Organoids in December 2024, strengthening its next-generation biology portfolio with organoid technology, foundational patents, model-generation capabilities, assay development, and high-throughput screening services. The transaction expands Merck's ability to support academia, biotechnology, and pharmaceutical customers with advanced 3D cell-culture solutions.

Molecular Devices / Danaher - Acquisition of Cellesce
Molecular Devices acquired Cellesce to integrate standardized, patient-derived organoid technology with automated organoid screening capabilities. The combination is designed to support large-scale drug screening using reproducible human-derived organoid models and strengthen commercial adoption of 3D biology platforms.

Merck KGaA - Partnership with Promega
Merck and Promega entered a strategic partnership in 2025 to co-develop technologies for drug screening using 3D cell cultures and organoids. The collaboration combines Merck's organoid and chemistry expertise with Promega's assay and reporter technologies to enable real-time cellular activity monitoring and higher-throughput screening.

MD Anderson Cancer Center & TOPPAN Holdings - Personalized cancer treatment collaboration
MD Anderson and TOPPAN Holdings announced a strategic alliance to advance TOPPAN's invivoidTM 3D cell-culture technology for cancer treatment evaluation and drug screening. The collaboration aims to develop organoid-based clinical tools capable of helping evaluate patient-specific treatment responses.

InSphero - Acquisition of DOPPL SA and Gri3D technology
InSphero announced the acquisition of DOPPL SA to combine scalable spheroid technologies with organoid platforms, including Sun Bioscience's Gri3D technology. The transaction strengthens its portfolio for high-throughput safety testing, disease modeling, and patient-derived organoid applications.

New Product/Technology Launches & Deployments
Recent innovations and deployments in the organoids space:

HUB Organoids - IntegriGut Screen
HUB Organoids introduced the IntegriGut Screen, an IBD patient-derived organoid monolayer screening service designed to evaluate epithelial barrier function and accelerate the development of therapies for inflammatory bowel disease.

STEMCELL Technologies - Advanced organoid culture platforms
STEMCELL Technologies has expanded its organoid research capabilities through advanced 3D cell models and culture solutions aimed at improving reproducibility and scalability in disease research, drug discovery, and personalized medicine. Its IntestiCult platform also supports cancer-derived intestinal organoid research and drug-response studies.

Thermo Fisher Scientific - Organoid growth media and culture tools
Thermo Fisher Scientific has expanded its organoid-focused portfolio with growth media and laboratory tools designed for complex tissue modeling, supporting pharmaceutical and academic research workflows requiring more consistent and physiologically relevant 3D models.

Merck KGaA - Optimized organoid reagents and culture systems
Merck has strengthened its organoid solutions with optimized reagents and culture systems targeting high-throughput screening and next-generation biology applications, building on its acquisition of HUB Organoids.

InSphero - Integrated 3D organoid and spheroid platforms
InSphero's integration of DOPPL and Gri3D technology expands access to reproducible organoid formation and automated workflows, supporting applications ranging from high-throughput drug screening and safety testing to complex disease-specific models.

R&D & Technological Advancements
Bioprinted organoids and spatial tissue engineering
Research is increasingly combining organoids with 3D bioprinting to precisely control tissue architecture, cellular composition, extracellular matrix structure, and vascularization. These approaches are being investigated for disease modeling, drug screening, and regenerative medicine.

AI-enabled organoid optimization
Artificial intelligence and computational modeling are emerging as important tools for optimizing organoid development, analyzing complex biological datasets, selecting bioinks and culture conditions, and improving the predictive performance of organoid-based models.

Patient-derived organoids for precision medicine
Research and commercial development are increasingly focused on patient-derived organoids that retain important characteristics of individual tumors and tissues, enabling personalized drug-response testing, disease modeling, and therapeutic evaluation.

Organoid-on-chip and microfluidic integration
Integration of organoids with microfluidic and organ-on-chip technologies is improving control over cellular microenvironments, drug exposure, and tissue interactions, creating more physiologically relevant models for pharmaceutical research.

High-throughput and standardized organoid production
R&D is increasingly focused on automated culture, standardized protocols, scalable manufacturing, and reproducible organoid batches to overcome variability and enable broader pharmaceutical and CRO adoption.

Multi-omics integration and advanced disease modeling
Organoid platforms are being combined with genomics, transcriptomics, proteomics, and other multi-omics approaches to better characterize disease mechanisms and improve the predictive power of therapeutic screening and precision medicine applications.

Unlock & Gain Complete 360° Market Visibility:
https://www.datamintelligence.com/buy-now-page?report=organoids-market?sindhuri

Segments Covered in the Global Organoids Market:
By Product Type:
The market includes intestinal organoids (25%), hepatic (20%), pancreatic (12%), colorectal (12%), neural (18%), and others (13%). Intestinal organoids dominate due to their widespread use in disease modeling, drug screening, toxicity testing, and intestinal research. Hepatic and neural organoids are growing rapidly, supported by increasing applications in liver and neurological disease research.

By Application:
The market covers bio-banking (10%), infectious disease pathology (8%), personalized medicine (15%), biomedical research and drug discovery (25%), regenerative medicine (12%), cancer research (15%), therapeutic tools (8%), and others (7%). Biomedical research and drug discovery lead due to increasing use of organoids for disease modeling, drug screening, and toxicity testing. Personalized medicine and cancer research are also expanding through patient-specific models.

By End-User:
The market is segmented into biopharmaceutical companies (45%), contract research organizations (25%), and academic and research institutes (30%). Biopharmaceutical companies dominate due to growing adoption of organoids in drug discovery and preclinical testing. CROs are expanding as pharmaceutical and biotechnology companies increasingly outsource organoid-based research.

By Region:
North America - 38% Share: Leads due to strong biotechnology investments, advanced 3D cell culture adoption, and the presence of major pharmaceutical and research organizations.

Europe - 28% Share: Growth is supported by investments in regenerative medicine, stem cell research, drug discovery, and translational medicine.

Asia-Pacific - 24% Share: Rapidly expanding with rising biotechnology investments, pharmaceutical research, and adoption of advanced cell culture technologies across China, Japan, South Korea, and India.

Contact Us -
Company Name: DataM Intelligence Contact
Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.